Tests a simulation to reduce stigma toward sickle cell patients among pharmacists
Tests an empathy simulation for pharmacists caring for sickle cell patients.
Key facts
- Who runs it
- Ohio State University
- Where
- Columbus, United StatesSee the site
- Trial code
- Registry title
- Solving Stigma Through POV Simulation: Enhancing Pharmacist Empathy-based Practices With Sickle Cell Disease Patients
- Status
- Not yet recruiting
- People taking part
- 200 people, planned
- Started
- 1 Sept 2026
- Expected to end
- 31 Jul 2027
- Type of study
- Interventional, 2 groupsOne group gets a sham (pretend) treatment, for comparison.
- Treatments tested
- point of view simulation
- Control
- Record updated
- 1 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for working healthcare professionals or healthcare students who can fill opioid prescriptions. It tests a simulation to build empathy toward sickle cell patients.
- Age
- 18 Years and older
- Sex
- Women and men
Main reasons for not taking part
- Not currently practicing or rotating in a clinical setting that fills opioid prescriptions
The registry criteria, word for word
Show all 3 criteriaShow less
Who can take part
- Practicing healthcare professional OR student in a healthcare professional program
- Ability to fill opioid prescriptions
Who cannot take part
- Not currently practicing or rotating in a clinical setting that fills opioid prescriptions
Where in United States
- Ohio State University College of PharmacyColumbus, United StatesContact: Nicholas Denton, PhDNo longer taking part
About the trial
What the trial wants to find out
Why This Research Matters (Significance)
Read full original descriptionShow less
1 in 5 of the 50+ million people with chronic pain in the U.S. face stigma when using opioids, especially women and racial minorities. This stigma often comes from pharmacy staff treating chronic pain patients as drug seekers, who then refuse to fill the patient's script, and leave the patient in severe pain. The team has found that having pharmacists watch testimonial videos of sickle cell patients sharing their pain management struggles can help reduce these misconceptions. However, using point of view simulations could be even more effective in fostering empathy among pharmacists. The goal is to create an educational simulation that helps pharmacists better understand and manage pain in sickle cell patients, ultimately improving their care.
What Makes This Research Unique (Innovation) Traditional methods to address biases in healthcare include watching patient testimonials or using expensive actors to play a standardized patient interaction to health professionals. This innovative point of view simulations engage participants' empathy more effectively by playing back what participants told the patient from the patient's point of view and are more accessible by having participants interact with the simulation on the computer any time and any place, rather than organizing a paid actor to visit the hospital. With advancements in artificial intelligence, we can create interactive simulations where virtual patients respond dynamically to questions, making the experience more realistic and impactful.
How Will the Researchers Conduct the Research (Approach)
The researchers will test if point of view simulations can reduce misconceptions among healthcare professionals and improve pain management for sickle cell patients. Here's the plan:
1. Create and Implement the Simulation: Use it as part of the training for pharmacy and hospital staff, as well as nursing and pharmacy students. 2. Survey Participants: Before and after the simulation, participants will take a survey to measure their misconceptions about opioid use. 3. Follow-Up: Six months later, researchers will survey the participants' patients and their managers to see if there's been an improvement in the empathetic care the participants provided.
The 2 groups in the trial
- POV simulationTreatment being tested
Participating pharmacists in the experimental arm will receive an email invitation to complete a 16-item pre-survey around opioid use misconceptions before completing the point of view simulation activity. 10 days after participants complete the simulation they will be invited to complete the opioid misconception survey again as a post-learning intervention assessment. 6 months after participants complete the simulation, their practice site will be visited by a sickle cell disease patient evaluator who will refill their opioid medication with the pharmacist and then complete an 11-item evaluation survey on the pharmacist's empathy-based pharmacy practices.
Treatment: point of view simulation
- ControlSham treatment, for comparison
Participating pharmacists in the sham arm will receive an email invitation to complete a 16-item pre-survey around opioid use misconceptions before completing an unrelated hematology educational activity. 10 days after participants complete the simulation they will be invited to complete the opioid misconception survey again as a post-learning intervention assessment. 6 months after participants complete the simulation, their practice site will be visited by a sickle cell disease patient evaluator who will refill their opioid medication with the pharmacist and then complete an 11-item evaluation survey on the pharmacist's empathy-based pharmacy practices.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Solving Stigma Through POV Simulation: Enhancing Pharmacist Empathy-based Practices With Sickle Cell Disease Patients
- Plain-language title
- Tests a simulation to reduce stigma toward sickle cell patients among pharmacistsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 1 July 2026